Reata Pharmaceuticals Inc (RETA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Reata Pharmaceuticals Inc (RETA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7594
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Reata Pharmaceuticals Inc (Reata) is a clinical-stage biopharmaceutical company that develops innovative medicines for the treatment of serious and life-threatening diseases. The company’s clinical candidates include bardoxolone methyl and omaveloxolone, which target Nrf2, a transcription factor, for restoring mitochondrial function, reducing oxidative stress, and resolving inflammation. Reata is evaluating bardoxolone methyl in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), Alport syndrome and other kidney diseases; and omaveloxolone in Friedreich’s ataxia. The company works in partnership with academics, biotechnology and pharmaceutical companies to develop technologies, which disrupt the pathophysiological processes that lead to intractable diseases. Reata is headquartered in Irving, Texas, the US.

Reata Pharmaceuticals Inc (RETA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
CNS Pharma Enters into Agreement with Reata Pharma 10
Licensing Agreements 11
Reata Pharma Enters into Licensing Agreement with University of Kansas 11
Equity Offering 12
Reata Pharma Raises USD248.4 Million in Public Offering of Shares 12
Reata Pharma Plans to Raise up to USD50 Million in Public Offering 14
Reata Pharma Raises USD115.8 Million in Public Offering of Shares 15
Reata Pharma Withdraws Public Offering of Shares for up to USD86.3 Million 17
Reata Pharma Raises USD69.6 Million in IPO of Shares 19
Reata Pharmaceuticals Inc – Key Competitors 21
Reata Pharmaceuticals Inc – Key Employees 22
Reata Pharmaceuticals Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 08, 2018: Reata Pharmaceuticals announces second quarter 2018 financial results and an update on development programs 24
May 08, 2018: Reata Pharmaceuticals Announces First Quarter 2018 Financial Results and an Update on Development Programs 26
Mar 02, 2018: Reata Pharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial and Operating Results 28
Nov 13, 2017: Reata Pharmaceuticals Announces Third Quarter 2017 Financial and Operating Results 30
Aug 14, 2017: Reata Pharmaceuticals Announces Second Quarter 2017 Financial and Operating Results 32
May 11, 2017: Reata pharmaceuticals announces first quarter 2017 financial and operating results 34
Mar 03, 2017: Reata Pharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial and Operating Results 36
Corporate Communications 38
Mar 02, 2017: Reata Pharmaceuticals Announces the Retirement of Board Member Dennis Stone, M.D., and the Addition of New Board Member William D. McClellan, Jr. 38
Product Approvals 39
Jun 22, 2017: Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Omaveloxolone for the Treatment of Friedreich’s Ataxia 39
Clinical Trials 40
Jun 01, 2017: Reata Pharmaceuticals Announces Positive Data From Part One of Moxie Trial of Omaveloxolone for Friedreich’s Ataxia 40
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Reata Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
CNS Pharma Enters into Agreement with Reata Pharma 10
Reata Pharma Enters into Licensing Agreement with University of Kansas 11
Reata Pharma Raises USD248.4 Million in Public Offering of Shares 12
Reata Pharma Plans to Raise up to USD50 Million in Public Offering 14
Reata Pharma Raises USD115.8 Million in Public Offering of Shares 15
Reata Pharma Withdraws Public Offering of Shares for up to USD86.3 Million 17
Reata Pharma Raises USD69.6 Million in IPO of Shares 19
Reata Pharmaceuticals Inc, Key Competitors 21
Reata Pharmaceuticals Inc, Key Employees 22
Reata Pharmaceuticals Inc, Subsidiaries 23

List of Figures
Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Reata Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Reata Pharmaceuticals Inc (RETA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Crescita Therapeutics Inc (CTX):企業の財務・戦略的SWOT分析
    Summary Crescita Therapeutics Inc (Crescita Therapeutics) is a commercial dermatology company that offers prescription drug products for the treatment and care of skin conditions and diseases and their symptoms. The company’s products comprise Pliaglis, Alyria, Laboratoire Dr Renaud, Pro-Derm, Premi …
  • UPL Ltd (UPL):企業の財務・戦略的SWOT分析
    UPL Ltd (UPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Cloverdale Paint Inc:企業の戦略的SWOT分析
    Cloverdale Paint Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Cafe De Coral Holdings Limited:企業の戦略・SWOT・財務分析
    Cafe De Coral Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Cafe De Coral Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • United Rentals Inc:戦略・SWOT・企業財務分析
    United Rentals Inc - Strategy, SWOT and Corporate Finance Report Summary United Rentals Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • SM Prime Holdings, Inc.:企業の戦略・SWOT・財務情報
    SM Prime Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary SM Prime Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Nuance Communications Inc (NUAN):医療機器:M&Aディール及び事業提携情報
    Summary Nuance Communications Inc (Nuance) is a provider of speech and imaging solutions. The company, offers solutions such as optical character recognition (OCR), automated speech recognition, capabilities for natural language understanding, domain knowledge and implementation capabilities, dialog …
  • Citigroup Inc:戦略・SWOT・企業財務分析
    Citigroup Inc - Strategy, SWOT and Corporate Finance Report Summary Citigroup Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Synthos SA:企業の戦略的SWOT分析
    Synthos SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Nutricia GmbH:企業の戦略的SWOT分析
    Nutricia GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • RWE AG (RWE):企業の財務・戦略的SWOT分析
    RWE AG (RWE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Endo International Plc (ENDP):企業の財務・戦略的SWOT分析
    Endo International Plc (ENDP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Waters Corporation (WAT)-医療機器分野:企業M&A・提携分析
    Summary Waters Corporation (Waters) is an analytical instrument manufacturing company. It carries out the design, production, commercialization and servicing of analytical technologies such as high performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC), chromatograp …
  • FunPep Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary FunPep Co Ltd (FunPep) is a biotechnology venture company that focuses on the development of peptides. The company’s pipeline products include SR-0379 functional peptide and FPP003 antibody inducing peptide. It uses smart peptide research integrated technology for developing functional pepti …
  • VTT Technical Research Centre of Finland-製薬・医療分野:企業M&A・提携分析
    Summary VTT Technical Research Centre of Finland (VTT) is a research and technology center that offers development services. The center provides research services on bioeconomy and circular economy, health and wellbeing, digital society, low carbon energy, smart industry, sustainable and smart city, …
  • HeartWare International Inc-医療機器分野:企業M&A・提携分析
    Summary HeartWare International Inc (HeartWare), subsidiary of Medtronic Plc is a medical device company that develops and manufactures ventricular assist devices and implantable heart pumps for the treatment of advanced heart failure. The company provides HeartWare Ventricular Assist System that co …
  • Votorantim SA:企業の戦略的SWOT分析
    Votorantim SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • MorphoSys AG (MOR):製薬・医療:M&Aディール及び事業提携情報
    Summary MorphoSys AG (Morphosys) is a developer of monoclonal antibodies for therapeutic, diagnostic and research applications. The company’s pipeline product includes MOR208, MOR202, MOR103, MOR106, and MOR107. It drugs are used for the treatment of various types of cancers, psoriasis, rheumatoid a …
  • Owens‑Illinois, Inc.:企業の戦略・SWOT・財務情報
    Owens‑Illinois, Inc. - Strategy, SWOT and Corporate Finance Report Summary Owens‑Illinois, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Hiscox Ltd:戦略・SWOT・企業財務分析
    Hiscox Ltd - Strategy, SWOT and Corporate Finance Report Summary Hiscox Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆